Clinical Trial: Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
Study Status: Completed
Recruit Status: RECRUITING
Condition: Gastric Cancer
Study Type: INTERVENTIONAL
Official Title: A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5863, a T Cell-engaging Bispecific Antibody That Ta
Brief Summary:
This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors.
Read more